Back to search results

Cognitive Rehabilitation for Breast Cancer Survivors

This study is looking at whether a type of therapy called Metacognitive Strategy Training (MCST) can help breast cancer survivors who have trouble with thinking, memory, and problem-solving after treatment. This is often called cancer-related cognitive impairment (CRCI). You might be able to join if you are a woman between 20 and 75 years old, have completed breast cancer treatment (Stages I, II, or III) 6 months to 3 years ago, and report issues with your thinking. The study will compare MCST to an inactive control group that receives weekly phone calls. Researchers will look at how well participants can perform daily activities and how satisfied they are with their performance, both before and after the 12-week intervention. The study aims to enroll 50 participants, but its current status is unclear.

Study design
This is an interventional study with an estimated enrollment of 50 participants. It compares Metacognitive Strategy Training (MCST) to an inactive control group.
What's involved
You will identify five daily life goals with a therapist. Measurements will be taken before the intervention (week 0) and after 12 weeks.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoints are measured after 12 weeks, which is the end of the intervention period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06545045

Cognitive Rehabilitation Following Breast Cancer Treatment

Recruiting
NAAges 20–75InterventionalTreatment
University of Missouri-Columbia
~50 participants
Updated 2026-02-19 on ClinicalTrials.gov
What's tested:Metacognitive Strategy Training (MCST)Inactive Control Group

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility measures
Measured over After study completion, an average of 12 weeks
+2 more outcomes measured

Conditions

Breast Cancer Female

Explore related trials

Breast CarcinomaCancer-Related Cognitive Impairment

Where it's being run

1 sites across 1 states
Missouri1

Study leadership

  • Anna E Boone, PhD, OTR/L · PRINCIPAL_INVESTIGATOR · University of Missouri Occupational Therapy

Who to contact

Anna E. Boone, PhD, OTR/L
[email protected]
5738827023
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

self-reported CRCI (Global Rating of Cognition dysfunction as "Moderately" "Strongly "or "Extremely" AND a Cognitive Failures Questionnaire1 (CFQ) score \>30)
completed treatment for active cancer diagnosis (invasive ductal or lobular BrCA Stages I, II, or III) at least 6 months but not greater than 3 years prior to participation
able to read, write, and speak English fluently
able to provide valid informed consent
have a life expectancy of greater than 6 months at time of enrollment
on stable doses (i.e., no changes in past 90 days) of medications that are known to impact cognitive function (i.e., anti-depressants)

Exclusion

prior cancer diagnoses of other sites with evidence of active disease within the past year
active diagnoses of any acute or chronic brain-related neurological conditions that can alter normal brain anatomy or function (e.g., Parkinson's disease, dementia, cerebral infarcts) dementia symptoms as indicated by a score of \<23 on the Montreal Cognitive Assessment (MoCA)
severe depressive symptoms (Personal Health Questionnaire-9 (PHQ-9) score of ≥21)
history of severe traumatic brain injury, prolonged loss of consciousness (e.g., coma)
conditions contraindicated for MRI (e.g., electrical implants, pumps, claustrophobia)
blue-yellow colorblindness
pregnancy

What this trial measures

  • Feasibility measuresAfter study completion, an average of 12 weeks

    Recruitment rate, retention rate

  • Canadian Occupational Performance Measure (COPM) PerformancePre-intervention (week 0) and post-intervention (week 12)

    Self-report measure of activity performance. Minimum = 1, Maximum = 10. Higher scores mean better performance.

  • Canadian Occupational Performance Measure (COPM) SatisfactionPre-intervention (week 0) and post-intervention (week 12)

    Self-report measure of activity performance. Minimum = 1, Maximum = 10. Higher scores mean better performance.